India’s Matrix To Hold Controlling Interest In Astrix Joint Venture
This article was originally published in PharmAsia News
U.S.-based Mylan Laboratories and its Indian arm, Matrix Laboratories, have agreed that Mylan will buy a half interest in Astrix Laboratories, a joint venture that makes anti-retroviral active pharmaceutical ingredients. Matrix and Aspen Pharmacare Holdings of South Africa formed Astrix as a joint venture, but decided last year that Matrix would buy out Aspen's 50 percent share. Instead, the plan now is to have Mylan, Matrix's parent, buy 49 percent of Aspen's shares through another Mylan subsidiary and Matrix's immediate parent, MP Laboratories of Mauritius. Matrix, already a 50 percent owner, is to buy the remaining 1 percent for control of Astrix. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.